Intelecta

Levocarnitine, the active ingredient in Intelecta, is a carnitine presented as an oral supplement for oral use. It is used to treat primary and secondary carnitine deficiency and to support fatty‑acid metabolism in patients with metabolic disorders. GNH USA supplies Intelecta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Intelecta (levocarnitine) acts on the carnitine pathway to correct deficiencies and improve fatty‑acid oxidation. - Primary carnitine deficiency: restores normal carnitine levels and improves energy metabolism. - Secondary carnitine deficiency due to metabolic disorders: supplements deficient carnitine to support fatty‑acid oxidation. - Support of fatty‑acid metabolism in mitochondrial disorders: enhances β‑oxidation and may reduce fatigue.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring after dosing. - Abdominal discomfort: cramping or pain in the stomach area. - Fishy odor in urine: characteristic smell due to metabolite excretion. - Headache: occasional mild headache. - Vomiting: occasional emesis after intake.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or swelling. - Anaphylaxis: severe, life‑threatening allergic response. - Severe rash or Stevens‑Johnson syndrome: extensive skin involvement. - Cardiac arrhythmia: irregular heart rhythm in susceptible patients. - Metabolic acidosis: abnormal blood pH levels. - Seizures: rare neurologic events.

Before initiating therapy, consider the following precautions: - Assess renal function: adjust use in severe renal impairment. - Monitor plasma carnitine levels: ensure therapeutic range is achieved. - Avoid in patients with known hypersensitivity to levocarnitine. - Use caution during pregnancy and breastfeeding: limited safety data available. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Levocarnitine may interact with several medicines. Major Interactions (Avoid): - Concurrent use with valproic acid: increased risk of hyperammonemia. - High‑dose carnitine during dialysis: reduced efficacy of treatment. - Co‑administration with carbapenem antibiotics: potential binding and reduced absorption. Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may alter metabolic response. - Statins: monitor for muscle‑related symptoms. - Alcohol consumption: may increase hepatic load and affect metabolism.